Incidence and risk factors of hypertension therapy in Australian cancer patients treated with vascular signalling pathway inhibitors

BACKGROUND: Clinical trials report systemic hypertension is an adverse effect of vascular signalling pathway inhibitor (VSPi) use. There are limited data from routine clinical practice. We aimed to estimate the real-world incidence and risk factors of new-onset and aggravated hypertension for cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Soojung, Daniels, Benjamin, van Leeuwen, Marina T., Pearson, Sallie-Anne, Vajdic, Claire M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777550/
https://www.ncbi.nlm.nih.gov/pubmed/35201530
http://dx.doi.org/10.1007/s12672-022-00468-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777550/
https://www.ncbi.nlm.nih.gov/pubmed/35201530
http://dx.doi.org/10.1007/s12672-022-00468-3

Ejemplares similares